Many physicians often fulfill patient requests for brand-name drugs instead of equivalent generics

7 January 2013

More than a third of U.S. physicians responding to a national survey indicated they often or sometimes prescribed brand-name drugs when appropriate generic substitutes were available simply because patients requested the brand-name drug. Survey respondents who had marketing relationships with industry were more likely to fulfill such patient requests than were those without those relationships. The report from investigators at the Mongan Institute for Health Policy (MIHP) at Massachusetts General Hospital (MGH) will appear in JAMA Internal Medicine (formerly Archives of Internal Medicine) and has been released online.

"The good news is that 63 percent of physicians indicated they never or rarely prescribed a brand-name drug instead of an equivalent generic simply because of a patient request. However, our data suggest that a substantial percentage – 37 percent or about 286,000 physicians nationally – do meet those requests," says Eric G. Campbell, PhD, of the MIHP, who led the study. "Since generics are from 30 to 80 percent cheaper than the brand-name versions, that would represent a significant source of unnecessary health costs."

Physicians who had been in practice more than 30 years were significantly more likely than those in practice for less time to report filling patient requests for brand-name drugs, as were physicians in solo or two-person practices. Internal medicine and psychiatry were the specialties most likely to honor such requests. Receiving industry-sponsored food or beverages in the workplace and receiving free drug samples – both of which are common marketing practices of pharmaceutical companies – were associated with a greater likelihood of prescribing brand-name drugs, although no association was seen with industry-paid speaking or consulting or with receiving industry gifts or reimbursement of travel expenses.

"While we cannot prove a cause-and-effect between industry marketing activities and prescribing practices, at the most basic level these data suggest that industry marketing works," says Campbell, a professor of Medicine at Harvard Medical School. "Our results also raise serious doubts about the desirability of meeting with drug company representatives to 'stay up to date'."

The authors note that measures to reduce unnecessary brand-name prescribing should include efforts to educate patients – who are targeted by drug-company advertising – as well as physicians about how wasteful the practice can be. Hospitals and health systems could require drug samples to go through their pharmacies, instead of directly to prescribing physicians, and could ban industry-provided food and beverages from their premises. Another option would be making the decision to prescribe a brand-name or generic drug the primary responsibility of pharmacists – which is currently the case in the U.S. Veteran's Health Administration – while allowing physicians to stipulate a brand-name drug for special circumstances.
Study co-author Christine Vogeli, PhD, of the MIHP, adds, "Reducing or eliminating this practice represents low-hanging fruit in terms of reducing unnecessary spending in medicine. However, doing so will likely be unpopular with some patients, physicians and certainly with the drug industry."

Additional co-authors of the JAMA Internal Medicine research letter are Genevieve Pham-Kanter, PhD, of the MIHP and the Safra Center for Ethics at Harvard University and Lisa Iezzoni, MD, director of the MIHP. The current study and overall survey were supported by a grant from the Institute on Medicine as a Profession at Columbia University.

Provided by Massachusetts General Hospital


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.